Pediatrics in Maine: Fall 2021 Educational Series - 11-2

Atopic Dermatitis and Psoriasis

Presented by Peter A. Lio, MD

Question Title

* 1. Will this activity enhance your competence or encourage you do anything differently after attending?

Yes

Optional - share an example:

Question Title

* 2. Will this activity influence your practice or patient outcomes?

Yes

Not sure

Comment:

Question Title

* 3. Was the presence of faculty conflict of interest or commercial support provided to the audience prior to the activity?

Yes

N/A

If yes, please specify:

Question Title

* 4. Please share your impressions of the speaker and presentation by rating the following:

	Excellent	Good	Fair	Poor
Presentation Style	Presentation Style Excellent	Presentation Style Good	Presentation Style Fair	Presentation Style Poor
Knowledge of Material	Knowledge of Material Excellent	Knowledge of Material Good	Knowledge of Material Fair	Knowledge of Material Poor
Relevance of Topic	Relevance of Topic Excellent	Relevance of Topic Good	Relevance of Topic Fair	Relevance of Topic Poor
Connection with Audience	Connection with Audience Excellent	Connection with Audience Good	Connection with Audience Fair	Connection with Audience Poor

Comments:

Question Title

* 5. Are there any topics you would like to see covered in future webinars - and/or - would you like a follow up (perhaps to go more in-depth on one particular topic) to this session?

Question Title

* 6. What is your specialty?

Internist

Pediatrician

Dermatologist

Allergist

Other (please specify)

Question Title

* 7. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 8. How many patients with AD do you manage?

1-25

26-50

51-100

100+

I am not directly involved in patient care

Question Title

* 9. Please select the best option that best describes your practice setting:

Academic medical center

Community hospital or medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 10. How confident are you in the management of patients with AD in your practice? (Please answer before hearing the talk, and after hearing the talk.)

	Very confident	Confident	Neutral	Slightly confident	Not confident
Before hearing this talk	Before hearing this talk Very confident	Before hearing this talk Confident	Before hearing this talk Neutral	Before hearing this talk Slightly confident	Before hearing this talk Not confident
After hearing this talk	After hearing this talk Very confident	After hearing this talk Confident	After hearing this talk Neutral	After hearing this talk Slightly confident	After hearing this talk Not confident

Question Title

* 11. How would you classify the severity of AD in a patient with perceptible erythema, papulation, and lichenification with mild oozing?

	Mild	Moderate	Severe
Before hearing this talk	Before hearing this talk Mild	Before hearing this talk Moderate	Before hearing this talk Severe
After hearing this talk	After hearing this talk Mild	After hearing this talk Moderate	After hearing this talk Severe

Question Title

* 12. In addition to basic management comprising skin care and trigger avoidance, which of the following treatments would you prescribe for a patient with marked erythema, induration, and lichenification affecting 40% of the body, including the face and hands?

TCI

TCS

Crisaborole

Dupilumab

Question Title

* 13. What proportion of pediatric patients with moderate-to-severe AD do you think have been shown to achieve ≥75% improvement in lesion extent and severity when dupilumab is combined with TCS therapy?

	30%	50%	70%
Before hearing this talk	Before hearing this talk 30%	Before hearing this talk 50%	Before hearing this talk 70%
After hearing this talk	After hearing this talk 30%	After hearing this talk 50%	After hearing this talk 70%

Question Title

* 14. How do you think the rate of ISGA (Investigator’s Static Global Assessment) success in crisaborole-treated infants 3 to <24 months compare with that observed in previous studies of similarly treated patients ≥ 2 years?

	Significantly greater	Significantly lower	Similar
Before hearing this talk	Before hearing this talk Significantly greater	Before hearing this talk Significantly lower	Before hearing this talk Similar
After hearing this talk	After hearing this talk Significantly greater	After hearing this talk Significantly lower	After hearing this talk Similar

Question Title

* 15. Casey is a 7 year old with a 5 year history of mild-to-moderate AD. His parents report that, despite diligent treatment with a TCI, he frequently wakes up during the night due to itching, and that his behavior and academic performance at school are increasingly being affected. According to current best practice recommendations, what is the most appropriate next step for Casey?

A switch to a different topical anti-inflammatory

A step up in treatment to a biologic therapy or a systemic immunosuppressant

Referral to a specialist

Question Title

* 16. If you are seeking CME, please attest below:

I watched the entire hour long webinar.

Yes

Question Title

* 17. Provide your full name and credentials and your email address.

Name

Email Address

Pediatrics in Maine: Fall 2021 Educational Series - 11-2

Atopic Dermatitis and Psoriasis

Question Title

* 1. Will this activity enhance your competence or encourage you do anything differently after attending?

Question Title

* 2. Will this activity influence your practice or patient outcomes?

Question Title

* 3. Was the presence of faculty conflict of interest or commercial support provided to the audience prior to the activity?

Question Title

* 4. Please share your impressions of the speaker and presentation by rating the following:

Question Title

* 5. Are there any topics you would like to see covered in future webinars - and/or - would you like a follow up (perhaps to go more in-depth on one particular topic) to this session?

Question Title

* 6. What is your specialty?

Question Title

* 7. How many years have you been in practice?

Question Title

* 8. How many patients with AD do you manage?

Question Title

* 9. Please select the best option that best describes your practice setting:

Question Title

* 10. How confident are you in the management of patients with AD in your practice? (Please answer before hearing the talk, and after hearing the talk.)

Question Title

* 11. How would you classify the severity of AD in a patient with perceptible erythema, papulation, and lichenification with mild oozing?

Question Title

* 12. In addition to basic management comprising skin care and trigger avoidance, which of the following treatments would you prescribe for a patient with marked erythema, induration, and lichenification affecting 40% of the body, including the face and hands?

Question Title

* 13. What proportion of pediatric patients with moderate-to-severe AD do you think have been shown to achieve ≥75% improvement in lesion extent and severity when dupilumab is combined with TCS therapy?

Question Title

* 14. How do you think the rate of ISGA (Investigator’s Static Global Assessment) success in crisaborole-treated infants 3 to <24 months compare with that observed in previous studies of similarly treated patients ≥ 2 years?

Question Title

Question Title

* 16. If you are seeking CME, please attest below: I watched the entire hour long webinar.

Question Title

* 17. Provide your full name and credentials and your email address.

* 16. If you are seeking CME, please attest below:

I watched the entire hour long webinar.